



4,723 were deemed healthcare-associated and underwent WGS. EDS-HAT identified 478 (12.2%) isolates genetically related to ≥ 1 other isolate across 173 clusters. Epidemiological links were found in 278 (58.2%) isolates in 114 clusters, with the majority being unit-based (205 isolates, 71.9%); other epidemiological links included equipment or healthcare workers (32 isolates, 11.5%), external facilities (24 isolates, 8.6%), and shared endoscopes (17 isolates, 6.1%); all endoscope outbreaks were effectively contained at two patients. No epidemiological links could be identified for 200 (41.8%) isolates. Infection prevention initiated 134 interventions in 114 clusters, including 74 (55.2%) general staff notification and education, 25 (18.7%) enhanced cleaning efforts, 23 (17.2%) hand hygiene/personal-protective equipment compliance observations, 9 (6.7%) environmental cultures, and 3 (2.2%) enhanced microbiological surveillance. Following the detection of an epidemiological link and intervention, 94/101 (94.1%) outbreaks were effectively halted on the intervened route (Figure). **Conclusion:** This study demonstrates the feasibility and efficacy of EDS-HAT as an infection prevention tool. Early detection and intervention of outbreaks significantly enhance the capability of healthcare facilities to control and prevent the spread of HAIs. Investment in infrastructure and implementation costs will result in reducing pathogen transmission and improving patient safety in acute care settings.

Disclosure: Alexander Sundermann: Honoraria - Opgen

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s113-s114

doi:10.1017/ash.2024.269

Presentation Type:

Poster Presentation - Poster Presentation

Subject Category: MRSA/VRE

Assessing chlorhexidine resistance in MRSA isolates from hospitals in Cleveland, OH and Detroit, MI

Collin Telchik, Department of Internal Medicine, Baylor Scott and White Medical Center, Temple, Texas; Chetan Jinadatha, Central Texas Veterans Health Care System; Jennifer Cadnum, Cleveland VA Medical Center; Curtis Donskey, Cleveland VA Medical Center; Piyali Chatterjee, Central Texas Veterans Health Care System; Sorabh Dhar, Harper Unive Hosp; Keith Kaye, Rutgers Robert Wood Johnson Medical School; Taylor Yakubik, Baylor Scott and White; Munok Hwang, Central Texas VA Research Foundation and Andrea Grimbergen, Baylor Scott and White

Background: Methicillin-resistant *Staphylococcus aureus* (MRSA) is one of the most common causes of procedure-related, skin, and soft-tissue infections. Hospitalized patients who are colonized with MRSA are at a higher risk of developing invasive infections after discharge. Chlorhexidine, an antiseptic/disinfectant, has been used to reduce carriage and prevent infections in these patients. Studies have shown chlorhexidine resistance among MRSA strains. Chlorhexidine resistance is associated

with *qac* genes, which encode multidrug efflux pumps that increase bacterial tolerance to disinfectant agents. The global distribution and prevalence of *qacA* and *qacB* genes are highly variable. One study reported that *qacA* and *qacB* genes could be found in 0.9% - 83.3% of clinical MRSA isolates worldwide. The goal of this study was to determine the prevalence of chlorhexidine resistance and identify the resistance-associated genes from our MRSA samples using whole genome sequencing (WGS). **Methods:** 474 MRSA samples were obtained from hospitals in Detroit, MI (287) and Cleveland, OH (187). Whole genome sequencing was performed using the NextSeq (Illumina Inc., CA) platform. The sequencing data was analyzed using ResFinder 4.1, a publicly available database that can be used to identify acquired genes and chromosomal mutations mediating antimicrobial resistance. The output was organized into a data sheet to visualize the presence of the genes of interest. **Results:** The *qacA* gene was present in only one MRSA sample from the Cleveland area hospital. In the samples from Detroit, 14 out of 287 showed disinfectant resistance genes. The *qacA*, *qacB*, and *qacD* were present in 1, 6, and 7 samples, respectively. The prevalence of any *qac* gene in the Cleveland area samples was 0.5%. Meanwhile, the prevalence of any *qac* gene in Detroit area samples was 4.9%. Among the 7 samples that have *qacD* gene, 6 samples have more than one copy of *qacD*. **Conclusions:** The prevalence of the “*qac*” gene varied widely based on the origin of the samples. Detroit area samples had more *qac* genes prevalence than Cleveland area samples. Chlorhexidine is a widely used antiseptic/disinfectant, and it plays a vital role in reducing carriage and preventing infection among hospitalized patients colonized with MRSA. Monitoring and addressing MRSA-reduced susceptibility to chlorhexidine is imperative for maintaining the effectiveness of infection control practices such as decolonization.

Antimicrobial Stewardship & Healthcare Epidemiology 2024;4(Suppl. S1):s114

doi:10.1017/ash.2024.270

Presentation Type:

Poster Presentation - Poster Presentation

Subject Category: MRSA/VRE

Timesavers: Clinical Decision Support and Automation of MRSA and VRE Deisolation

Molly Paras, Massachusetts General Hospital; Rebecca Craig, Massachusetts General Hospital; Lindsay Germaine, Mass General Brigham; Chloe Green, Infection Control; Zoe Vernick, Massachusetts General Hospital; Jasmine Ha, MGB Digital and Erica Shenoy, Massachusetts General Hospital, Mass General Brigham

Background: Most healthcare facilities in the US apply contact precautions (CP) for patients with methicillin-resistant *Staphylococcus aureus* (MRSA) or vancomycin-resistant enterococci (VRE) infection and/or colonization. Most individuals with MRSA or VRE colonization will clear over time; however, frontline clinicians rarely evaluate for discontinuation of CP, resulting in increased burden on infection preventionists (IPs). Automation of time- and test-based evaluation using clinical decision support systems (CDSS) embedded in electronic health records (EHR) may increase evaluation and discontinuation of CP when appropriate, while preserving IP resources. **Methods:** This quality improvement initiative was implemented at Mass General Brigham (MGB), an integrated healthcare system, where patients with MRSA or VRE infection/colonization are identified in the EHR with a corresponding “infection status” and CP applied. Following MGB policy (Figure 1), CDSS features included: 1) automated time-based resolution from 2/15/2023-11/13/2023 and 2) automated ordering of screening assays for patients eligible for test-based evaluation from 6/20/2023-11/14/2023 (Figure 2). Counts of CP discontinuation and automated ordering were performed. IPs at one MGB facility performing manual review of patients self-recorded the time spent evaluating for CP discontinuation. Using these time reports, the average time to complete these tasks and the projected time savings were calculated over the implementation period. **Results:** Four IPs recorded the time to review patients for CP discontinuation, including reviewing recent antimicrobial administration, microbiology results, ordering screening test(s), and